Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system - PubMed (original) (raw)
. 2004 Nov 1;173(9):5776-85.
doi: 10.4049/jimmunol.173.9.5776.
Marie H Kosco-Vilbois, Suzanne Herren, Rocco Cirillo, Valeria Muzio, Paola Zaratin, Michela Carbonatto, Matthias Mack, Amir Smailbegovic, Mark Rose, Rebecca Lever, Clive Page, Timothy N C Wells, Amanda E I Proudfoot
Affiliations
- PMID: 15494530
- DOI: 10.4049/jimmunol.173.9.5776
Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system
Zoë Johnson et al. J Immunol. 2004.
Abstract
A hallmark of autoimmunity and other chronic diseases is the overexpression of chemokines resulting in a detrimental local accumulation of proinflammatory immune cells. Chemokines play a pivotal role in cellular recruitment through interactions with both cell surface receptors and glycosaminoglycans (GAGs). Anti-inflammatory strategies aimed at neutralizing the chemokine system have to-date targeted inhibition of the receptor-ligand interaction with receptor antagonists. In this study, we describe a novel strategy to modulate the inflammatory process in vivo through mutation of the essential heparin-binding site of a proinflammatory chemokine, which abrogates the ability of the protein to form higher-order oligomers, but retains receptor activation. Using well-established protocols to induce inflammatory cell recruitment into the peritoneal cavity, bronchoalveolar air spaces, and CNS in mice, this non-GAG binding variant of RANTES/CCL5 designated [44AANA47]-RANTES demonstrated potent inhibitory capacity. Through a combination of techniques in vitro and in vivo, [44AANA47]-RANTES appears to act as a dominant-negative inhibitor for endogenous RANTES, thereby impairing cellular recruitment, not through a mechanism of desensitization. [44AANA47]-RANTES is unable to form higher-order oligomers (necessary for the biological activity of RANTES in vivo) and importantly forms nonfunctional heterodimers with the parent chemokine, RANTES. Therefore, although retaining receptor-binding capacity, altering the GAG-associated interactive site of a proinflammatory chemokine renders it a dominant-negative inhibitor, suggesting a powerful novel approach to generate disease-modifying anti-inflammatory reagents.
Similar articles
- A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice.
Braunersreuther V, Steffens S, Arnaud C, Pelli G, Burger F, Proudfoot A, Mach F. Braunersreuther V, et al. Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1090-6. doi: 10.1161/ATVBAHA.108.165423. Epub 2008 Apr 3. Arterioscler Thromb Vasc Biol. 2008. PMID: 18388327 - Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3.
Chvatchko Y, Proudfoot AE, Buser R, Juillard P, Alouani S, Kosco-Vilbois M, Coyle AJ, Nibbs RJ, Graham G, Offord RE, Wells TN. Chvatchko Y, et al. J Immunol. 2003 Nov 15;171(10):5498-506. doi: 10.4049/jimmunol.171.10.5498. J Immunol. 2003. PMID: 14607956 - A non-glycosaminoglycan-binding variant of CC chemokine ligand 7 (monocyte chemoattractant protein-3) antagonizes chemokine-mediated inflammation.
Ali S, Robertson H, Wain JH, Isaacs JD, Malik G, Kirby JA. Ali S, et al. J Immunol. 2005 Jul 15;175(2):1257-66. doi: 10.4049/jimmunol.175.2.1257. J Immunol. 2005. PMID: 16002730 - Anti-chemokine therapy for inflammatory diseases.
Castellani ML, Bhattacharya K, Tagen M, Kempuraj D, Perrella A, De Lutiis M, Boucher W, Conti P, Theoharides TC, Cerulli G, Salini V, Neri G. Castellani ML, et al. Int J Immunopathol Pharmacol. 2007 Jul-Sep;20(3):447-53. doi: 10.1177/039463200702000303. Int J Immunopathol Pharmacol. 2007. PMID: 17880758 Review. - The biological relevance of chemokine-proteoglycan interactions.
Proudfoot AE. Proudfoot AE. Biochem Soc Trans. 2006 Jun;34(Pt 3):422-6. doi: 10.1042/BST0340422. Biochem Soc Trans. 2006. PMID: 16709177 Review.
Cited by
- Pleiotropic Effects of Heparin and its Monitoring in the Clinical Practice.
Arachchillage DJ, Kitchen S. Arachchillage DJ, et al. Semin Thromb Hemost. 2024 Nov;50(8):1153-1162. doi: 10.1055/s-0044-1786990. Epub 2024 May 29. Semin Thromb Hemost. 2024. PMID: 38810964 Free PMC article. Review. - Heterodimers Are an Integral Component of Chemokine Signaling Repertoire.
Kaffashi K, Dréau D, Nesmelova IV. Kaffashi K, et al. Int J Mol Sci. 2023 Jul 19;24(14):11639. doi: 10.3390/ijms241411639. Int J Mol Sci. 2023. PMID: 37511398 Free PMC article. Review. - Rapid Internalization and Nuclear Translocation of CCL5 and CXCL4 in Endothelial Cells.
Dickhout A, Kaczor DM, Heinzmann ACA, Brouns SLN, Heemskerk JWM, van Zandvoort MAMJ, Koenen RR. Dickhout A, et al. Int J Mol Sci. 2021 Jul 8;22(14):7332. doi: 10.3390/ijms22147332. Int J Mol Sci. 2021. PMID: 34298951 Free PMC article. - Location, location, location: how the tissue microenvironment affects inflammation in RA.
Buckley CD, Ospelt C, Gay S, Midwood KS. Buckley CD, et al. Nat Rev Rheumatol. 2021 Apr;17(4):195-212. doi: 10.1038/s41584-020-00570-2. Epub 2021 Feb 1. Nat Rev Rheumatol. 2021. PMID: 33526927 Review. - Targeting Chemokine-Glycosaminoglycan Interactions to Inhibit Inflammation.
Crijns H, Vanheule V, Proost P. Crijns H, et al. Front Immunol. 2020 Mar 31;11:483. doi: 10.3389/fimmu.2020.00483. eCollection 2020. Front Immunol. 2020. PMID: 32296423 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical